Research programme: janus kinase inhibitors - Aclaris Therapeutics

Drug Profile

Research programme: janus kinase inhibitors - Aclaris Therapeutics

Alternative Names: Baricitinib - Aclaris Therapeutics; Decernotinib - Aclaris Therapeutics; JAK inhibitors; Ruxolitinib - Aclaris Therapeutics; Tofacitinib - Aclaris Therapeutics

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia University
  • Developer Aclaris Therapeutics
  • Class Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Vitiligo
  • Research Alopecia

Most Recent Events

  • 24 Oct 2017 The Columbia University receives a Notice of Allowance from the United States Patent and Trademark Office for tofacitinib in Alopecia
  • 22 Sep 2017 Japan Patent Office issues Japanese Letters Patent No. 6 212 107 for tofacitinib in Alopecia
  • 05 Sep 2017 Columbia University and Aclaris Therapeutics have patent protection for Janus kinase inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top